EP4259065A1 - Dérivés de tétrahydrocannabinol à base de silicium et leurs compositions - Google Patents
Dérivés de tétrahydrocannabinol à base de silicium et leurs compositionsInfo
- Publication number
- EP4259065A1 EP4259065A1 EP20835965.3A EP20835965A EP4259065A1 EP 4259065 A1 EP4259065 A1 EP 4259065A1 EP 20835965 A EP20835965 A EP 20835965A EP 4259065 A1 EP4259065 A1 EP 4259065A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- silicon
- tetrahydrocannabinol
- derivative according
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 title claims abstract description 88
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229910052710 silicon Inorganic materials 0.000 title claims abstract description 54
- 239000010703 silicon Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960004242 dronabinol Drugs 0.000 claims abstract description 46
- 230000000699 topical effect Effects 0.000 claims abstract description 15
- 238000009472 formulation Methods 0.000 claims abstract description 12
- 229910002808 Si–O–Si Inorganic materials 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- -1 allylic halide Chemical class 0.000 claims description 23
- 125000000524 functional group Chemical group 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 7
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 5
- 229910000077 silane Inorganic materials 0.000 claims description 4
- 125000005401 siloxanyl group Chemical group 0.000 claims description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 235000017807 phytochemicals Nutrition 0.000 claims description 3
- 229930000223 plant secondary metabolite Natural products 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims 3
- SLLGVCUQYRMELA-UHFFFAOYSA-N chlorosilicon Chemical compound Cl[Si] SLLGVCUQYRMELA-UHFFFAOYSA-N 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 229910052990 silicon hydride Inorganic materials 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000002210 silicon-based material Substances 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- SWGZAKPJNWCPRY-UHFFFAOYSA-N methyl-bis(trimethylsilyloxy)silicon Chemical compound C[Si](C)(C)O[Si](C)O[Si](C)(C)C SWGZAKPJNWCPRY-UHFFFAOYSA-N 0.000 description 3
- 150000004756 silanes Chemical class 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- JUKDCZINIGGOFM-UHFFFAOYSA-N CCC[Si](CCC)(CCC)OC(CC[SiH3])O[Si](CCC)(CCC)CCC Chemical compound CCC[Si](CCC)(CCC)OC(CC[SiH3])O[Si](CCC)(CCC)CCC JUKDCZINIGGOFM-UHFFFAOYSA-N 0.000 description 1
- SOLDVZFDLYFBHR-UHFFFAOYSA-N CCC[Si](CCC)(CCC)OC(C[SiH3])O[Si](CCC)(CCC)CCC Chemical compound CCC[Si](CCC)(CCC)OC(C[SiH3])O[Si](CCC)(CCC)CCC SOLDVZFDLYFBHR-UHFFFAOYSA-N 0.000 description 1
- AJZFNGACQFAICM-UHFFFAOYSA-N CC[Si](CC)(CC)OC(CC[SiH3])O[Si](CC)(CC)CC Chemical compound CC[Si](CC)(CC)OC(CC[SiH3])O[Si](CC)(CC)CC AJZFNGACQFAICM-UHFFFAOYSA-N 0.000 description 1
- DUGNOCZIJBRFBZ-UHFFFAOYSA-N CC[Si](CC)(CC)OC(C[SiH3])O[Si](CC)(CC)CC Chemical compound CC[Si](CC)(CC)OC(C[SiH3])O[Si](CC)(CC)CC DUGNOCZIJBRFBZ-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001343 alkyl silanes Chemical class 0.000 description 1
- 125000005376 alkyl siloxane group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical class OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000006459 hydrosilylation reaction Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000003961 organosilicon compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 1
- IXEXMSWSWDRVIF-UHFFFAOYSA-N triethyl-[silyl(triethylsilyloxy)methoxy]silane Chemical compound CC[Si](CC)(CC)OC([SiH3])O[Si](CC)(CC)CC IXEXMSWSWDRVIF-UHFFFAOYSA-N 0.000 description 1
- YUYCVXFAYWRXLS-UHFFFAOYSA-N trimethoxysilane Chemical compound CO[SiH](OC)OC YUYCVXFAYWRXLS-UHFFFAOYSA-N 0.000 description 1
- WAQGZSSSGDJLFT-UHFFFAOYSA-N trimethyl-(2-silyl-1-trimethylsilyloxyethoxy)silane Chemical compound C[Si](C)(C)OC(C[SiH3])O[Si](C)(C)C WAQGZSSSGDJLFT-UHFFFAOYSA-N 0.000 description 1
- CGUJEDGTPGPQRV-UHFFFAOYSA-N trimethyl-(3-silyl-1-trimethylsilyloxypropoxy)silane Chemical compound C[Si](C)(C)OC(CC[SiH3])O[Si](C)(C)C CGUJEDGTPGPQRV-UHFFFAOYSA-N 0.000 description 1
- PBADBUWJLFERAM-UHFFFAOYSA-N tripropyl-[silyl(tripropylsilyloxy)methoxy]silane Chemical compound CCC[Si](CCC)(CCC)OC([SiH3])O[Si](CCC)(CCC)CCC PBADBUWJLFERAM-UHFFFAOYSA-N 0.000 description 1
- ZHOVAWFVVBWEGQ-UHFFFAOYSA-N tripropylsilane Chemical compound CCC[SiH](CCC)CCC ZHOVAWFVVBWEGQ-UHFFFAOYSA-N 0.000 description 1
- ZQTYRTSKQFQYPQ-UHFFFAOYSA-N trisiloxane Chemical compound [SiH3]O[SiH2]O[SiH3] ZQTYRTSKQFQYPQ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0838—Compounds with one or more Si-O-Si sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- Tetrahydrocannabinol is a phytocannabinoid which is known to have antiinflammatory activity. It is the primary psychoactive cannabinoid and is known to bind to cannabinoid receptors (CB 1 and CB2) to reduce pain, inflammation, and hyperalgesia (see, for example, Citti et al, Sci. Rep. 9, 20335 (2019); Karsak et al, Science, 316,1494 (2007);
- Tetrahydrocannabinol is the designated name for (6a7?,10a7?)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-67/-benzo[c]chromen-l-ol, shown below:
- a silicon-based tetrahydrocannabinol derivative according to an embodiment of the disclosure contains a silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having Formula (I):
- a topical or dermatological formulation according to an embodiment of the disclosure contains a base formulation and at least one silicon-based tetrahydrocannabinol derivative comprising at least one silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule having Formula (I):
- the disclosure relates to compositions containing derivatives of tetrahydrocannabinol (THC) containing a silicon-containing functional group which are beneficial for various applications, including the formulation of topical medicinal products and personal care products, and methods for their preparation.
- THC tetrahydrocannabinol
- the silicon-containing tetrahydrocannabinol derivatives described herein are unique hybrid organosilicon compounds formed by attaching tetrahydrocannabinol to a siloxane backbone, also described as a molecule comprising one silicon-based functional group containing Si-O-Si bonds which is bound to a tetrahydrocannabinol molecule.
- cannabinoid acceptors of the compounds described herein has not yet been studied, they are expected to provide increased stability and solubility and to release the free tetrahydrocannabinol uniformly and over a prolonged period.
- tetrahydrocannabinol and THC are intended to encompass all isomers of tetrahydrocannabinol, including those found naturally or developed synthetically.
- Preferred embodiments of the compounds of the disclosure include trisiloxanyl derivatives of tetrahydrocannabinol in which a siloxane-based group is bound through the phenolic hydroxyl group of the tetrahydrocannabinol molecule, forming an Si-O-C bond.
- the silicon-based tetrahydrocannabinol derivatives include a tetrahydrocannabinol molecule, such as shown in Formula (I), having a silicon-based group as a functional group. Most preferably, the silicon-based group is a siloxanyl group or a trialkoxysilane- containing group.
- Preferred tetrahydrocannabinol derivatives described herein have a structure in accordance with Formula (I) above in which the phenolic hydroxyl group is bound to a siloxane moiety containing two or more silicon atoms, preferably three or more silicon atoms, most preferably about 3 to about 10 silicon atoms.
- Tetrahydrocannabinol derivatives according to embodiments of the invention have general formula (A).
- R may be, for example and without limitation, SiMe(OSiMe 3 )2, SiMe2(OSiMe2)4CH2CH2CH 2 CH3, SiMe 2 OSiMe3, and SiMe 2 OSiMe2C 6 H5, in which “Me” is a methyl group.
- compounds having formula (A) that are within the scope of the disclosure are not limited to these substituents, and other silicon-containing functional groups having Si-O-Si bonds that are known in the art or to be developed would also be suitable for R.
- Substituents containing a single silicon atom without an oxane (oxygen) bridge between two or more silicon atoms are not within the scope of the disclosure because such tetrahydrocannabinol derivatives fail to provide acceptable film-forming properties.
- simple trialkylsilyl derivatives, as well as derivatives containing only alkyl, aryl, hydrogen, halogen, vinyl, allyl and/or alkoxy substituents on the silicon are not within the scope of the disclosure as these are not effective for the intended purpose.
- Other compounds within the scope of the disclosure include polydimethylsiloxanes in which the tetrahydrocannabinol substitutes through the phenolic oxygen in place of a methyl group on a polydimethylsiloxane, such as Me3Si(OSiMe2)m(OSiMeTHC)nSiMe3, in which “THC” represents tetrahydrocannabinol, Me is a methyl group, and m and n are integers.
- m is 1 to about 100 and n is 1 to about 10.
- the silicon-based tetrahydrocannabinol derivatives according to embodiments of the disclosure include a wide variety of derivatized compounds, including most preferred compounds such as, for example, (tetrahydrocannabinoloxy)heptamethyltrisiloxane (formula (II)), tetrahydrocannabinoloxy-terminated polydimethylsiloxane (formula (III)), and tetrahydrocannabinoloxypropyl-terminated polydimethylsiloxane (formula (IV)), shown below, in which m and n are integers; preferably m is 1 to about 100 and n is 1 to about 10.
- Compounds according to embodiments of the disclosure may contain a direct ether linkage between the silicon-containing functional group and the phenolic hydroxyl group of the tetrahydrocannabinol molecule (direct Si-0 bond) or may contain an alkyl group spacer between the phenolic hydroxyl group on tetrahydrocannabinol and the silicon-based functional group, such as compounds in which R in formula (A) is CfbSiNfeOSiMes or CfbSiNfeOSiNfeCeHs.
- the spacer is not limited to CH2, and may also be a longer alkyl chain containing up to about 11 carbon atoms, such as (CH2)3, which, along with CH2, is also a preferred embodiment.
- Compounds according to embodiments of the disclosure which contain an alkyl group spacer between the phenolic hydroxyl group on tetrahydrocannabinol and the silicon-based functional group may have general formula (B) below, in which R’ is a silicon-based group and x is an integer ranging from 1 to about 11, preferably 1 (methyl) to 3 (propyl). Most preferably, the silicon-based group is a siloxanyl group or a trialkoxysilane-containing group.
- R’ may be, for example and without limitation, SiMe(OSiMe3)2, SiMe2(OSiMe2)4CH2CH2CH2CH3, SiMe2OSiMe3, or SiMe2OSiMe2CeH5, in which Me is methyl.
- Direct Si-0 linkage of the tetrahydrocannabinol derivatives may result in diminished allergic inflammation by releasing free tetrahydrocannabinol over a prolonged period by slow hydrolysis.
- the Si-0 bond on tetrahydrocannabinol derivatives is not stable when exposed to moisture, which results in slow decomposition of compounds to form free tetrahydrocannabinol and low molecular weight siloxanes.
- the silane-based tetrahydrocannabinol derivatives are anticipated to be stable when stored in air and protected from moisture. They are anticipated to show bioactivity in medicinal applications either directly or by slow hydrolysis to form underivatized THC.
- silicones and silicone derivatives are easily incorporated into topical or dermatological products, including anti-inflammatory and palliative formulations, due to their solubility in a range of polar compounds such as castor oil and a variety of cosmetic or dermatological vehicles. They may also act as co-solvents for silicones. Further, due to such solubility, these derivatives may be useful as compatibilizers for other bioactives, such as unmodified cannabidiol and tetrahydrocannabinol compounds, among other possible applications.
- the tetrahydrocannabinol derivatives described herein may be prepared by various synthetic pathways.
- the compounds may be prepared by reacting the hydroxyl group on the benzenoid ring of tetrahydrocannabinol with an allylic halide in a solvent to form an allyloxytetrahydrocannabinol intermediate, and then hydrosilylating the intermediate with a silane compound and catalyst to form a silicon-based tetrahydrocannabinol derivative with a spacer.
- a direct Si-0 linkage on the hydroxyl group of tetrahydrocannabinol by reacting the hydroxyl group (C-OH) with a chlorine-containing siloxane compound (-Si-Cl) in the presence of a base acceptor, or by the dehydrogenative coupling of the hydroxyl group with a hydride- containing siloxane compound (-Si-H).
- the silane compounds used in the reactions described above may be any of a wide variety of silicon-based compounds, and preferably include alkylsilanes, alkoxysilanes, alkylsiloxanes and alkoxysiloxanes and their derivatized or functionalized counterparts. In general, it is preferred to have two or more silicon atoms in the substitution in order to provide solubility and spreading characteristics suitable for topical creams and ointments.
- Examples include, without limitation, bis(trimethylsiloxy)methylsilane, bis(trimethylsiloxy)ethylsilane, bis(trimethylsiloxy)propylsilane, bis(triethylsiloxy)methylsilane, bis(triethylsiloxy)ethylsilane, bis(triethylsiloxy)propylsilane, triethoxysilane, trimethoxysilane, tripropylsilane, bis(tripropylsiloxy)methylsilane, bis(tripropylsiloxy)ethylsilane, bis(tripropylsiloxy)propylsilane and similar compounds.
- silane compounds herein are polymeric silicon-containing molecules having similar reactive capabilities as the silane monomeric structures noted above, such as polydimethylsiloxane, polydiethylsiloxane, poly dipropyl siloxane, polymethylethylsilane, polymethylpropylsiloxane, and other polyalkyl- or polyalkenyl-siloxanes as are known in the art or to be developed. Chain lengths may vary, but it is preferred that the molecular weight (Mn) of polymeric silane compounds used to form polymeric silicon-based derivative groups on tetrahydrocannabinol be from 100 to about 5000, and most preferably from about 500 to about 2000.
- Mn molecular weight
- the derivatives described herein may be produced using pure tetrahydrocannabinol.
- the derivatives may be formed and provided as a component of phytocannabinoid and/or other phytochemical mixtures.
- the tetrahydrocannabinol derivative of cannabis extracts may be formed without isolating the pure tetrahydrocannabinol component.
- compositions according to the invention may contain one or more of the derivatives described herein and one or more phytochemicals extracted from cannabis.
- the silicon-based tetrahydrocannabinols described herein may be used in various topical and dermatological compositions, including preferably those which have silicon compounds or silicone-based polymers in the base formulation because the derivatives facilitate compatibility and solubility in such compounds within formulations.
- the disclosure is not limited to those compositions and may include any topical or dermatological composition in which the silicon-based tetrahydrocannabinol derivatives are useful.
- the cosmetic and topical compositions of the present disclosure include a base formulation, which may be any suitable topical or dermatological base formulation as described above, and at least one silicon-based tetrahydrocannabinol derivative as described herein.
- the silicon-based tetrahydrocannabinol derivatives include a tetrahydrocannabinol molecule or a commercial or natural derivative thereof and include a silicon-based functional group bonded to the tetrahydrocannabinol molecule (or the derivative thereof) through the oxygen atom of the benzenoid ring.
- the silicon-based tetrahydrocannabinol derivative is present in an amount of about 0.01 percent by weight to about 20 percent by weight, preferably about 0.5 percent by weight to about 5 weight percent and most preferably about 0.5 to about 1.0 percent by weight based on the weight of the formulation.
- reaction mixture is filtered through silica gel (40g) and washed with tetrahydrofuran (400g). The filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by NMR and FTIR.
- Example 2 Synthesis of 1-butyl-l, 1,3, 3,5,5, 7,7,9,9-decamethyl-9-(((6aR,10aR)-6,6,9-trimethyl- 3 -pentyl-6a,7, 8, 10a-tetrahvdro-6H-benzol clchromen- 1 -yl)oxy)pentasiloxane (III)
- reaction mixture is filtered through silica gel (40g) and washed with tetrahydrofuran (400g). The filtrate is concentrated in vacuo. The residue contains the product and unreacted tetrahydrocannabinol and is analyzed by NMR and FTIR.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
L'invention concerne des dérivés de tétrahydrocannabinol à base de silicium et des procédés pour leur synthèse, les dérivés contenant une molécule de tétrahydrocannabinol et au moins un groupe à base de silicium contenant des liaisons Si-O-Si. Les dérivés sont utiles dans des compositions topiques et dermatologiques, ont des propriétés topiques bénéfiques potentielles, et améliorent la solubilité et la compatibilité dans des formulations topiques et dermatologiques contenant les matériaux à base de silicium.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2020/064235 WO2022125095A1 (fr) | 2020-12-10 | 2020-12-10 | Dérivés de tétrahydrocannabinol à base de silicium et leurs compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4259065A1 true EP4259065A1 (fr) | 2023-10-18 |
Family
ID=74125705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20835965.3A Pending EP4259065A1 (fr) | 2020-12-10 | 2020-12-10 | Dérivés de tétrahydrocannabinol à base de silicium et leurs compositions |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4259065A1 (fr) |
JP (1) | JP2023554329A (fr) |
KR (1) | KR20230143137A (fr) |
CN (1) | CN116685595A (fr) |
CA (1) | CA3201704A1 (fr) |
WO (1) | WO2022125095A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2854896B1 (fr) * | 2003-05-16 | 2007-08-17 | Mayoly Spindler Lab | Nouveaux tensioactifs, compositions les comprenant |
EP2176208B1 (fr) * | 2007-07-30 | 2015-01-21 | Zynerba Pharmaceuticals, Inc. | Promédicaments de cannabidiol, compositions comprenant les promédicaments de cannabidiol et leurs procédés d'utilisation |
WO2018148785A1 (fr) * | 2017-02-15 | 2018-08-23 | Botanix Pharmaceuticals Ltd | Formulations de cannabinoïdes pour le traitement de la dermatite et de maladies cutanées inflammatoires |
WO2018148787A1 (fr) * | 2017-02-15 | 2018-08-23 | Botanix Pharmaceuticals Ltd | Formulations de cannabinoïdes pour le traitement du psoriasis |
WO2020214574A1 (fr) * | 2019-04-15 | 2020-10-22 | Trustees Of Boston University | Synthèse à médiation par l'écoulement en une étape de cannabidiol (cbd) et de ses dérivés |
CN112047973B (zh) * | 2019-06-06 | 2022-11-18 | 上海科技大学 | 一种大麻素类化合物,其制备方法、组合物和用途 |
-
2020
- 2020-12-10 CA CA3201704A patent/CA3201704A1/fr active Pending
- 2020-12-10 JP JP2023535575A patent/JP2023554329A/ja active Pending
- 2020-12-10 CN CN202080107856.2A patent/CN116685595A/zh active Pending
- 2020-12-10 WO PCT/US2020/064235 patent/WO2022125095A1/fr active Application Filing
- 2020-12-10 EP EP20835965.3A patent/EP4259065A1/fr active Pending
- 2020-12-10 KR KR1020237023201A patent/KR20230143137A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022125095A1 (fr) | 2022-06-16 |
KR20230143137A (ko) | 2023-10-11 |
CA3201704A1 (fr) | 2022-06-16 |
JP2023554329A (ja) | 2023-12-27 |
CN116685595A (zh) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2777058B2 (ja) | 有機ケイ素化合物及びその製法 | |
KR100574573B1 (ko) | 카보실록산 덴드리머 | |
JP2014502271A5 (fr) | ||
FI94031C (fi) | Rodium-kolloidi, menetelmä sen valmistamiseksi ja sen käyttö | |
EP0661331B1 (fr) | Polymère contenant du silicium, procédé pour sa préparation et monomère | |
EP3154992A1 (fr) | Réactions d'hydrosilylation catalysée par le platine utilisant des additifs cyclodiène | |
US5539137A (en) | Aryl substituted silicone fluids having high refractive indices and method for making | |
CA2210586A1 (fr) | Esters de silanes cycliques et leurs produits de solvolyse; methodes de preparation de ces esters et de leurs produits de solvolyse | |
US11667655B2 (en) | Silicon-based tetrahydrocannabinol derivatives and compositions thereof | |
EP4259065A1 (fr) | Dérivés de tétrahydrocannabinol à base de silicium et leurs compositions | |
EP2632905A1 (fr) | Procédé pour la préparation de composés siloxanes à fonction 2-hydroxyphénylbenzotriazole | |
US5086127A (en) | Silicone UV absorbers containing silane units | |
CA2084733A1 (fr) | Cyclopolysiloxanes a groupe fonctionnel siloxy | |
US5693735A (en) | Trimethylsiloxy group-containing polysiloxane and a process for producing the same | |
US5239099A (en) | Azasilacycloalkyl functional alkoxysilanes and azasilacycloalkyl functional tetramethyldisiloxanes | |
US8653294B2 (en) | Silicones derived from 2-propenyl functional cyclic terpenes and methods of preparation | |
US3529007A (en) | New organosilicon compounds,their preparation and their use | |
CA2064379A1 (fr) | Procede de fabrication de certains nouveaux copolymeres de silicone polyether pour la fabrication de mousse de polyurethane | |
JP7156759B2 (ja) | ケイ素ベースのカンナビジオール誘導体及びその組成物 | |
WO2013191955A1 (fr) | Organopolysiloxanes monofonctionnels pour agents de compatibilité polyhétérosiloxanes | |
EP4410796A1 (fr) | Procédé de production d'un composé de polysiloxane modifié par alcoxysilyle alkylaminopropyle | |
JP7350253B2 (ja) | ビスハロアルキルシロキサン化合物及びその製造方法、並びに、両末端官能性のシロキサン化合物の製造方法 | |
US5162560A (en) | Olefinic and acetylenic azasilacyclopentanes | |
JPH0859836A (ja) | ラジカル形成基を有するオルガノシランおよびオルガノポリシロキサン、それらの製造法、マクロモノマーおよびグラフトコポリマーの製造法並びに変性された熱可塑性樹脂、珪素含有ポリマー配合物のための相容性助剤およびポリマー配合物中のシリコン成分 | |
JP2002097273A (ja) | オルガノポリシロキサン、およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230628 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |